Evidence map›Paper›PMID 9665488›Full record

ArticleThe American journal of pathology1998

Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast.

J H Lichy, M Zavar, M M Tsai, T J O'Leary, J K Taubenberger

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. TIP30: A Novel Tumor-Suppressor Gene.Oncology research · 2014
    Review
  3. CD81 is a candidate tumor suppressor gene in human gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2013
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The long and short of chromosome 11 in breast cancer.The American journal of pathology · 1998
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J H LichyMolecular Pathology Division, Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. lichy@email.afip.osd.mil
M Zavar
M M Tsai
T J O'Leary
J K Taubenberger
Armed Forces Institute of Pathology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microdissection of histologically identifiable components from formalin-fixed, paraffin-embedded tissue sections allows molecular genetic analyses to be correlated directly with pathological findings. In this study, we have characterized loss of heterozygosity (LOH) at chromosome 11p15 at different stages of progression in microdissected tumor components from 115 ductal carcinomas of the breast. Microdissected foci of intraductal, infiltrating, and metastatic tumors were analyzed to determine the stage of progression at which LOH at 11p15 occurs. LOH was detected in 43 (37%) of 115 cases. Foci of intraductal carcinoma could be microdissected from 85 cases, of which 30 (35%) showed LOH at some stage of progression. LOH was detected in the intraductal component in 26 of these 30 cases. Interstitial deletions were characterized by using a panel of 10 highly polymorphic markers. The smallest region of overlap (SRO) for LOH at 11p15 was bounded by the markers D11S4046 and D11S1758. LOH at 11p15.5 showed no correlation with estrogen receptor status, the presence of positive lymph nodes, tumor size, histological grade, or long-term survival. We conclude that 11p15 LOH usually occurs early in breast cancer development but less frequently does not develop until the infiltrating or metastatic stages of tumor progression.

Indexed as

Chromosomes, Human, Pair 11Breast NeoplasmsCarcinoma, Ductal, BreastHumansLoss of HeterozygosityLymphatic MetastasisSurvival Rate

Identifiers

PMID9665488
PMCPMC1852963
OpenAlexW2024117541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.